Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v6-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2022-10-06 | 2022-08-11 |
Drug Identification Number | 01997572 | 01997572 |
Brand name | DANTRIUM INTRAVENOUS | DANTRIUM INTRAVENOUS |
Common or Proper name | DANTROLENE SODIUM | DANTROLENE SODIUM |
Company Name | ENDO PAR INNOVATION COMPANY, LLC | ENDO PAR INNOVATION COMPANY, LLC |
Ingredients | DANTROLENE SODIUM | DANTROLENE SODIUM |
Strength(s) | 20MG | 20MG |
Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 6x20mg Vials | 6x20mg Vials |
ATC code | M03CA | M03CA |
ATC description | MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS | MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | ||
Actual start date | 2022-07-20 | 2022-07-20 |
Estimated end date | 2022-11-04 | 2022-10-10 |
Actual end date | ||
Shortage status | Actual shortage | Actual shortage |
Tier 3 Status | No | No |
Company comments | Limited quantity available on allocation under October, distributed by Paladin Labs PaladinCS@endo.com | Limited quantity available on allocation under October |
Health Canada comments |